跳至主要内容
临床试验/NCT06087705
NCT06087705招募中不适用

Real-life Assessment of the Safety and Performance of the SYNOVIUM HCS Device

LCA Pharmaceutical1 个研究点 分布在 1 个国家目标入组 134 人开始时间: 2023年2月7日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
134
试验地点
1
主要终点
device performance

研究概览

简要总结

Patients who are to benefit from an injection of SYNOVIUM HCS as part of their care will be offered to participate in this study. Patients will need to sign a consent form to participate. Prior to SYNOVIUM HCS injection, patients will be asked a series of questions regarding their pain and disability. Data collected during follow-up visits can be compared to pre-injection data.

详细描述

Inclusion period: 6 months

Follow-up period:

  • 6-month follow-up, after intra-articular injection with extension

  • 1 single syringe of SYNOVIUM HCS (3 mL),

  • Controls scheduled at 1 week, 1, 3, 6 months and up to 1 year

  • Additional control (single) in the event of leaving the study if this takes place outside the scheduled visit dates and before 1 year, for medical reasons

  • Duration of the study: Overall time estimated at 18 months

  • In this open-label CI, the group itself is used as a control, by comparing the scores on inclusion with those of the various control visits.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult patient
  • Patient with radiologically characterized gonarthrosis (stages Kellgren & Lawrence grades I to III)
  • Patient with walking pain (WOMAC A1) at least equal to 2 on the Likert scale 0-4
  • Patient to benefit from an injection of SYNOVIUM HCS as part of his treatment
  • Patient agreeing to participate in the study
  • Patient affiliated to a social security scheme or benefiting from such a scheme

排除标准

  • Viscosupplementation less than 6 months old
  • Intra-articular corticosteroid injection less than 2 months old
  • Inflammatory arthritis or active infectious of the knee studied
  • History of surgery of the lower limb concerned
  • Kellgren & Lawrence grades not defined
  • Known hypersensitivity to hyaluronic acid or chondroitin sulfate
  • Pregnant or breastfeeding women
  • Patient under guardianship, curatorship or judicial safeguard
  • Patient participating in another clinical investigation, at the time of inclusion

结局指标

主要结局

device performance

时间窗: 6 months

evolution of the pain sub-score of the WOMAC (universities of Western Ontario and McMaster) index (A). The higher the score, the more the knee osteoarthritis has a functional impact.

次要结局

  • responder patients(1 year)
  • Evolution of the pain(1 year)
  • Stiffness(1 year)
  • Impact of the injection on concomitant treatments(1 year)
  • Investigator's general assessment(1 year)
  • Complication(1 year)
  • recovery of autonomy(1 year)
  • Function(1 year)
  • long-term performance of the SYNOVIUM HCS device(1 year)

研究者

发起方
LCA Pharmaceutical
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验